Calithera Biosciences Gets Fast Track Designation for CB-839

June 7, 2017

Calithera Biosciences, a clinical stage biotechnology company developing novel cancer therapeutics, said Wednesday that the U.S. Food and Drug Administration has granted fast track designation to CB-839 in combination with everolimus, for the treatment of patients with metastatic renal cell carcinoma who have received two or more prior lines of therapy.

CB-839 is a first-in-class, oral, selective, potent inhibitor of glutaminase being evaluated in phase 1/2 clinical trials for the treatment of solid tumors including renal cell carcinoma, triple negative breast cancer, non-small cell lung cancer, and melanoma. The company said that it will be imitating a global randomized trial of CB-839 in combination with everolimus for the treatment of renal cell carcinoma in the second half of 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

By Bryan Smith

Free Email Newsletter


Enter your email address below to get the latest news and analysts' ratings for your stocks with MarketBeat's FREE daily email newsletter: